Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19180617 | 0.92 | POLB (0.57) | NT5EPOLBP2RY1ENPP1 | |
| SCHEMBL1069101 | 0.91 | POLB (0.56) | NT5EPOLBP2RY1ENPP1 | |
| SCHEMBL23501737 | 0.91 | NT5E (0.63) | NT5EPOLBP2RY1ENPP1 | |
| Triphosphate SCHEMBL28101757 | 0.87 | POLB (0.61) | NT5EPOLBP2RY1ENPP1 | |
| SCHEMBL1533826 | 0.87 | POLB (0.65) | NT5EPOLBP2RY1ENPP1 | |
| SCHEMBL1533828 | 0.87 | POLB (0.65) | NT5EPOLBP2RY1ENPP1 | |
| SCHEMBL20266303 | 0.86 | POLB (0.64) | NT5EPOLBP2RY1ENPP1 | |
| SCHEMBL10438039 | 0.84 | PNP (0.64) | — | |
| SCHEMBL855722 | 0.84 | PNP (0.64) | — | |
| SCHEMBL17117808 | 0.83 | NT5E (0.69) | NT5EPOLBP2RY1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3199639-B1 | NOVEL MEASUREMENT METHOD USING KINASE, AND COMPOSITION | ASAHI KASEI PHARMA CORP (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-10472665-B2 | Measuring method and composition using kinase | ASAHI KASEI PHARMA CORPORATION (JP) | 2019-11-12 | — | — | US | disclosed |
| US-20170306389-A1 | NOVEL MEASURING METHOD AND COMPOSITION USING KINASE | ASAHI KASEI PHARMA CORPORATION (JP) | 2017-10-26 | — | — | US | disclosed |
| EP-3199639-A1 | NOVEL MEASUREMENT METHOD USING KINASE, AND COMPOSITION | Asahi Kasei Pharma Corporation (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9365604-B2 | Oligomer-nucleoside phosphate conjugates | NEKTAR THERAPEUTICS (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140371168-A1 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-12-18 | — | — | US | disclosed |
| US-8741858-B2 | Oligomer-nucleoside phosphate conjugates | NEKTAR THERAPEUTICS | 2014-06-03 | — | — | US | disclosed |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009042064-A2 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371168-A1 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | ENTPD5, SLC29A2, SLC29A1 | NT5E 24/4885POLB 638/4885P2RY1 158/4885 |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | ENTPD5, SLC29A2, SLC29A1 | NT5E 25/4885POLB 665/4885P2RY1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.